Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
Provided herein are duplex oligonucleotide complexes which can be administered to a cell, tissue or organism to silence a target gene without the aid of a transfection reagent(s). The duplex oligonucleotide complexes of the disclosure include a conjugate moiety that facilitates delivery to a cell, tissue or organism.
1. A duplex oligonucleotide complex comprising:
a. a sense strand that is 19 nucleotides in length, wherein nucleotides 1 and 2 and all C nucleotides and all U nucleotides on said sense strand are 2′O-methyl modified;
b. an antisense strand that is 21 nucleotides in length, wherein:
i. all C nucleotides and all U nucleotides on said antisense strand are 2′ F modified;
ii. the antisense strand has 100% complementarity with a target mRNA and one mismatched nucleotide with the sense strand; and
iii. the sense strand and the antisense strand form a duplex having a 2 nucleotide overhang at the 3′ end of the antisense strand, said 2 nucleotide overhang comprising phosphorothioate linkages;
c. a cholesterol molecule attached to the 3′ end of the sense strand via a C5 linker molecule wherein the cholesterol-linker-sense strand has the structure:
d. a phosphate group at the 5′ end of the antisense strand; and
e. a mismatch between nucleotide 14 on the antisense strand and the opposite nucleotide 6 on the sense strand, wherein all other nucleotides on the sense strand are complementary to nucleotides on the antisense strand; and
wherein the duplex oligonucleotide complex is capable of entry into a cell by passive delivery.
2. A kit comprising a container, said container comprising:
(1) a duplex oligonucleotide complex comprising:
a. a sense strand that is 19 nucleotides in length, wherein nucleotides 1 and 2 and all C nucleotides and all U nucleotides on said sense strand are 2′O-methyl modified;
b. an antisense strand that is 21 nucleotides in length, wherein:
i. all C nucleotides and all U nucleotides on said antisense strand are 2′ F modified;
ii. the antisense strand has 100% complementarity with a target mRNA and one mismatched nucleotide with the sense strand; and
iii. the sense strand and the antisense strand form a duplex having a 2 nucleotide overhang at the 3′ end of the antisense strand, said 2 nucleotide overhang comprising phosphorothioate linkages;
c. a cholesterol molecule attached to the 3′ end of the sense strand via a C5 linker molecule wherein the cholesterol-linker-sense strand has the structure:
d. a phosphate group at the 5′ end of the antisense strand; and
e. a mismatch between nucleotide 14 on the antisense strand and the opposite nucleotide 6 on the sense strand; and
wherein the duplex oligonucleotide complex is capable of entry into a cell by passive delivery and wherein all other nucleotides on the sense strand are complementary to nucleotides on the antisense strand; and
(2) a reduced serum tissue culture medium.
3. The duplex oligonucleotide complex of claim 1 wherein:
the opposite nucleotide 6 on the sense strand is the same nucleotide that occurs on position 14 of the antisense strand.
4. The kit of claim 2 , wherein: the opposite nucleotide 6 on the sense strand is the same nucleotide that occurs on position 14 of the antisense strand.
5. The duplex oligonucleotide of claim 3 wherein the 2 nucleotide overhang at the 3′ end of the antisense strand is UU.
6. The duplex oligonucleotide of claim 5 wherein all nucleotides in the sense and antisense strands other than the nucleotides 1 and 2 of the sense strand and all C nucleotides and all U nucleotides of the sense and antisense strands comprise a 2′-OH.
7. The duplex oligonucleotide of claim 1 , wherein between about 40% and about 90% of the nucleotides of the sense strand and between about 40% and about 90% of the nucleotides of the antisense strand are chemically modified.